Skip to main content

Advertisement

SpringerLink
Log in

Using bone densitometry to monitor therapy in treating osteoporosis: Pros and cons

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Measurement of bone density is crucial for evaluating fracture risk. Low bone mass is a powerful predictor of fracture and is necessary to assess the need for treatment. Dual energy x-ray absorptiometry is accurate and precise. Use of bone density for monitoring therapy is an important tool for evaluating response to therapy, but an understanding of the limitations of the procedure are important for the practicing physician. Precision error of the technology and what change in density is clinically significant (least significant change) are important concepts to interpret results and make appropriate treatment decisions. This article reviews the use of bone densitometry as a tool for monitoring treatment in patients with low bone mass.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Curry JD: Power law models for the mechanical properties of cancellous bone. Eng Med 1986, 15:153–154.

    Google Scholar 

  2. Turner CH: Yield behavior of cancellous bone. J Biomech Eng 1989, 111:1–5.

    Article  Google Scholar 

  3. Hui SL, Slemenda CW, Johnston CC: Baseline measurement of bone mass predicts fracture in white women. Ann Int Med 1989, 111:355–361.

    PubMed  CAS  Google Scholar 

  4. Cummings SR, Black DM, Nevitt MC, et al.: Bone density at various sites for prediction of hip fractures. Lancet 1993, 341:72–75.

    Article  PubMed  CAS  Google Scholar 

  5. Melton JL, Atkinson EJ, O’Fallon WM, et al.: Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Mineral Res 1993, 8:1227–1233.

    Article  Google Scholar 

  6. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637–645.This is the major treatment trial for raloxifene (multiple outcomes of raloxifene evaluation [MORE]) showing vertebral fracture reduction.

    Article  PubMed  CAS  Google Scholar 

  7. Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535–1541.

    Article  PubMed  CAS  Google Scholar 

  8. Cummings SR, Black D: Should perimenopausal women be screened for osteoporosis? Ann Intern Med 1986, 104:817–823.

    PubMed  CAS  Google Scholar 

  9. Gluer CC: Monitoring skeletal changes by radiological techniques. J Bone Min Res 1999, 14:1952–1962.Provides summary of the concept of least significant change (LSC) and minimum change in BMD that is clinically significant. Also provides summary of precision error (PE) and monitoring time interval (MTI).

    Article  CAS  Google Scholar 

  10. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. JAMA 1998, 280:2077–2082.This is the clinical fracture arm of the fracture intervention trial (FIT II), fracture reduction demonstrated in a post hoc analysis in subjects with femoral neck T-scores of less than-2.5.

    Article  PubMed  CAS  Google Scholar 

  11. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344–1352.The North American arm of the VERT (vertebral efficacy with risedronate therapy) trial demonstrating reduction in vertebral fracture with risedronate, the second bisphosphonate to be marketed in the United States for the treatment of osteoporosis. Nonvertebral fractures were significantly lowered.

    Article  PubMed  CAS  Google Scholar 

  12. Reginster JY, Minne HW, Sorensen OH, et al.: Randomized trial of the effect of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000, 11:83–91.The European arm of the VERT trial demonstrating reduction in vertebral fracture with risedronate.

    Article  CAS  Google Scholar 

  13. Silverman SL, Chestnut C, Andriano K, et al.:Salmon calcitonin nasal spray reduces risk of vertebral fractures in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the PROOF Study. Jucta. Bone 1998, 23:S174.

    Google Scholar 

  14. Bush TL, Wells HB, James MK, et al.: Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996, 276:1389–1396.

    Article  Google Scholar 

  15. Hosking D, Clair ED, Chilvers DS, et al.: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998, 338:485–492.This is the EPIC (early prevention intervention cohort) trial showing efficacy of alendronate in a population of early postmenopausal women.

    Article  PubMed  CAS  Google Scholar 

  16. Miller PD, Bonnick SL, Johnston CC, et al.: The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? J Clin Densitometry 1998, 1:211–217. Demonstrates the need for central site Dexa (dual energy x-ray absorptiometry) to monitor patients on treatment for osteoporosis.

    Article  CAS  Google Scholar 

  17. Bouxsein M, Parker RA, Greenspan SL: Forearm bone density measurements cannot be used to monitor improvements in hip and spine bone density after 2.5 years of alendronate therapy. Bone 1998, 23:S312.

    Google Scholar 

  18. Reid IR, Evans MC, Ames R, Wattie DJ: The influence of osteophytes and aortic calcification on spinal mineral density in postmenopausal women. J Clin Endocrinol Metab 1991, 72:1372–1374.

    Article  PubMed  CAS  Google Scholar 

  19. Cummings SR, Palermo L, Browner W, et al.: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 2000, 283:1318–1321. Discusses regression to the mean, a phenomenon that occurs with measurements at the extremes; in this case, larger than expected gains or loses in BMD. These measurements tend to regress toward the mean change in the population over time.

    Article  PubMed  CAS  Google Scholar 

  20. Duong T, Brand R, Cummings SR: Has your patient responded to alendronate despite her vertebral fracture? J Bone Min Res 1999, 14:S505.

    Google Scholar 

  21. Faulkner K: Bone matters: are density increases necessary to reduce fracture risk? J Bone Min Res 2000, 15:183–187.Nice review of BMD and the skeletal and nonskeletal factors that influence the relationship between BMD and fractures.

    Article  CAS  Google Scholar 

  22. Black DM, Sarkar, Mitlak B, et al.: What proportion of the effects of raloxifene on vertebral fracture risk can be directly attributed to its BMD effects? J Bone Min Res 1999, 14:S158.

    Article  Google Scholar 

  23. Hughes BD, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670–676.An important article showing significant efficacy of calcium and vitamin D in preventing nonvertebral fractures, with small increases in BMD.

    Article  Google Scholar 

  24. Hochberg MC, Ross PD, Black D, et al.: Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999, 42:1246–1254. Demonstrates that patients in the FIT trials with larger increases in BMD (more than 30%) had greater reduction in fracture than those with smaller increases.

    Article  PubMed  CAS  Google Scholar 

  25. Washnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85:231–236. Argues that most (80%) of the reduction in vertebral fracture seen in published clinical trials is related to increases in BMD.

    Article  Google Scholar 

  26. Miller PD, Zapalowski C, Kulak CAM, Bilezikian JP: Bone densitometry: the best way to detect osteoporosis and monitor therapy. J Clin Endocrinol 1999, 84:1867–1871.Nice review of the importance of bone density in evaluation and treatment of patients with osteoporosis.

    Article  CAS  Google Scholar 

  27. McClung MR: Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. Bone 1996, 19:195s-198s.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatic & Immunologic Diseases, Center for Osteoporosis and Metabolic Disease, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A-50, 44195, Cleveland, OH, USA

    Chad L. Deal MD

Authors
  1. Chad L. Deal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deal, C.L. Using bone densitometry to monitor therapy in treating osteoporosis: Pros and cons. Curr Rheumatol Rep 3, 233–239 (2001). https://doi.org/10.1007/s11926-001-0023-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-001-0023-4

Keywords

Search

Navigation